Amneal (AMRX) Exec Exercises Options and Executes Large Share Sale on 08/20/2025
Rhea-AI Filing Summary
Andrew S. Boyer, Executive Vice President of Amneal Pharmaceuticals (AMRX), reported insider transactions executed on 08/20/2025. He exercised 175,000 stock options at a $2.75 exercise price, acquiring 175,000 Class A common shares. On the same date he sold 279,244 Class A common shares at a weighted average price of $9.38, with sale prices ranging from $9.30 to $9.40 per share.
After these transactions the Form 4 shows Mr. Boyer beneficially owned 431,670 Class A shares before the sale line and 152,426 Class A shares following the sale line, and held 97,480 options (derivative securities) after the reported option exercise. The filing was signed by an attorney-in-fact on 08/22/2025 and notes the exercised options were fully vested.
Positive
- Exercise of 175,000 fully vested options at a $2.75 strike, demonstrating realization of option value
- Full disclosure of sale price range (sales between $9.30 and $9.40) and weighted average price $9.38
Negative
- Significant share sale of 279,244 shares reduced reported direct beneficial ownership to 152,426 Class A shares
- Large insider liquidity event could be viewed as increased insider selling despite option exercise
Insights
TL;DR: Insider exercised a large number of vested options at a low strike and sold a larger block of shares the same day.
The filing documents a simultaneous option exercise and significant share sale by an executive. Exercising 175,000 options at a $2.75 strike realizes intrinsic value when shares trade near the reported sale prices of $9.30–$9.40. The disclosed weighted average sale price is $9.38. The net effect was a reduction in reported direct beneficial ownership to 152,426 Class A shares while leaving 97,480 options recorded post-transaction. These are routine Section 16 transactions but materially large in share count and thus relevant to investors tracking insider liquidity.
TL;DR: Transaction is documented and signed by attorney-in-fact; options are fully vested per the filer.
The Form 4 includes necessary disclosures: transaction codes, prices, quantities, and a footnote clarifying the weighted-average sale price range. The filing states the exercised options are fully vested, reducing potential questions about timing relative to vesting. The signature by an attorney-in-fact is properly noted with date 08/22/2025. No amendments or additional restrictive details are provided in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 175,000 | $0.00 | -- |
| Exercise | Class A Common Stock | 175,000 | $2.75 | $481K |
| Sale | Class A Common Stock | 279,244 | $9.38 | $2.62M |
Footnotes (1)
- The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.40 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. These options are fully vested.
